Nature Biotechnology published an article titled "Stock Options and Beyond" by Shearman & Sterling partner John J. Cannon III (New York-Compensation, Governance & ERISA) and of counsel Mark Kessel (New York-Capital Markets) on August 8, 2013.

In their article, Cannon and Kessel examine the advantages and disadvantages of stock options and the accounting, tax and other regulatory constraints associated with stock option programs and other equity-based remuneration.

View article, Stock Options and Beyond